The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
 
Weimin Li
No Relationships to Disclose
 
Sophie Wildsmith
Employment - AstraZeneca
 
Jiabu Ye
Employment - AstraZeneca
 
Han Si
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Nassim Morsli
Employment - AstraZeneca
 
Philip He
Employment - AstraZeneca
 
Jagdish Shetty
Employment - AstraZeneca
 
Alejandro Javier Yovine
Employment - AstraZeneca; Novartis
Stock and Other Ownership Interests - AstraZeneca; Novartis
 
Nicholas Holoweckyj
Employment - AstraZeneca
 
Rajiv Raja
Employment - AstraZeneca
 
Katia Real
Employment - AstraZeneca
 
Paul Scorer
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Todd Hembrough
Employment - AstraZeneca
 
Jill Walker
Employment - AstraZeneca
 
Qu Zhang
Employment - AstraZeneca
 
Ricard Mesia
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Nanobiotix; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Genentech; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst); VentiRx (Inst)
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen and Nanobiotics Sa; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Doxapharma; Eisai; GlaxoSmithKline; Incyte; Merck Serono; MSD; Nanobiotix; Novartis; Roche; SOBI
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck Serono; MSD
 
Robert L. Ferris
Consulting or Advisory Role - Aduro Biotech; Amgen; AstraZeneca/MedImmune; Bain Capital Life Sciences; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Iovance Biotherapeutics; Lilly; Macrogenics; Merck; Nanobiotix; Numab; Oncorus; Ono Pharmaceutical; Pfizer; PPD; Regeneron; Tesaro; Torque; TTMS; TTMS
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Tesaro; TTMS; VentiRx